Dr. Wayne R. Hogrefe

Nonagen Bioscience Corporation, USA

Email: [email protected]

Qualifications

1979 Ph.D., Case Western Reserve University, Experimental Pathology

1972 B.T., University of Dayton, Chemical Technology

Publications (selected)

1. Rhyne, P. W., Sunshine, J., Hogrefe, W., et al. (2026). Development and qualification of a multiplexed immunoassay to assess the immunogenicity of Shigella vaccines (vol. 68, 127896, 2025). Vaccine, 70, 128014.
2. Rhyne, P. W., Sunshine, J., Hogrefe, W., et al. (2025). Development and qualification of a multiplexed immunoassay to assess the immunogenicity of Shigella vaccines. Vaccine, 68, 127896.
3. Sakatani, T., Tanaka, S., Murakami, K., et al. (2025). Development and analytical validation of a multiplex diagnostic qPCR-array as a potential application in predicting the response to neoadjuvant chemotherapy in muscle invasive bladder cancer. Translational Oncology, 61, 102528.
4. Tanaka, S., Shimizu, T., Pagano, I., et al. (2025). Expanded Performance Comparison of the Oncuria 10-Plex Bladder Cancer Urine Assay Using Three Different Luminex xMAP Instruments. Diagnostics, 15(14), 1749.
5. Tanaka, S., Murakami, K., Sakatani, T., et al. (2025). Effects of Different Voided Urine Sample Storage Time, Temperature, and Preservatives on Analysis with Multiplex Bead-Based Oncuria Bladder Cancer Immunoassay. Diagnostics, 15(2), 138.
6. Tanaka, S., Murakami, K., Sakatani, T., et al. (2024). Effect of different voided urine sample storage time and temperature, and preservatives, on analysis with the multiplex bead-based Oncuria® bladder cancer immunoassay. Clinical Cancer Research, 30(21), A069.
7. Sakatani, T., Tanaka, S., Murakami, K., et al. (2024). Bladder cancer risk stratification with the Oncuria 10 plex bead-based urinalysis assay using three different Luminex xMAP instrumentation platforms. Clinical Cancer Research, 30(10), A006.
8. Tanaka, S., Sakatani, T., Murakami, K., et al. (2024). Bladder cancer risk stratification with the Oncuria 10 plex bead-based urinalysis assay using three different Luminex xMAP instrumentation platforms. Cancer Research, 84(6), 3773.
9. Furuya, H., Sakatani, T., Tanaka, S., et al. (2024). Bladder cancer risk stratification with the Oncuria 10-plex bead-based urinalysis assay using three different Luminex xMAP instrumentation platforms. Journal of Translational Medicine, 22(1), 8.
10. Yates, J. L., Hunt, D. T., Kulas, K. E., et al. (2023). Development of a novel serological assay for the detection of mpox infection in vaccinated populations. Journal of Medical Virology, 95(10), e29134.
11. Lee, W. T., Hunt, D. T., Kulas, K. E., et al. (2023). Development of a novel serology assay for the detection of IgG antibodies to identify exposures to orthopoxviruses. Journal of Immunology, 210(1).
12. Tapia, M. D., Sow, S. O., Ndiaye, B. P., et al. (2020). Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial. Lancet Infectious Diseases, 20(6), 707-718.
13. Tapia, M. D., Sow, S. O., Mbaye, K. D., et al. (2020). Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial. Lancet Infectious Diseases, 20(6), 719-730.
14. Mattiuzz, G., Knezevic, I., Hassall, M., et al. (2019). Harmonization of Zika neutralization assays by using the WHO International Standard for anti-Zika virus antibody. npj Vaccines, 4, 42.
15. Smith, J. S., Bailey, R. C., Westreich, D. J., et al. (2009). Herpes simplex virus type 2 antibody detection performance in Kisumu, Kenya, using the Herpeselect ELISA, Kalon ELISA, Western blot and inhibition testing. Sexually Transmitted Infections, 85(2), 92-96.
16. Benjamin, R. J., Busch, M. P., Fang, C. T., et al. (2008). Human immunodeficiency virus-1 infection correlates strongly with herpes simplex virus-2 (genital herpes) seropositivity in South African and United States blood donations. Transfusion, 48(2), 295-303.
17. Ngo, T. D., Laeyendecker, O., La, H., et al. (2008). Use of commercial enzyme immunoassays to detect antibodies to the herpes simplex virus type 2 glycoprotein G in a low-risk population in Hanoi, Vietnam. Clinical and Vaccine Immunology, 15(2), 382-384.
18. Laderman, E. I., Whitworth, E., Dumaual, E., et al. (2008). Rapid, sensitive, and specific lateral-flow immunochromatographic point-of-care device for detection of herpes simplex virus type 2-specific immunoglobulin G antibodies in serum and whole blood. Clinical and Vaccine Immunology, 15(1), 159-163.

Profile Details
https://www.nonagen.com/leadership
https://www.researchgate.net/profile/Wayne-Hogrefe